Laura Clague insider trades: Travere Therapeutics (TVTX) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Laura reports to the SEC
and 1 more company
Open-market buys and sales
24 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| May 11, 2022 | TVTX | ↓ Sell | 2,200 | $21.51 | $47K | Direct | May 12, 2022 (1d) |
| Feb 23, 2022 | GNSS | ↓ Sell | 13,716 | $3.14 | $43K | Direct | Feb 24, 2022 (1d) |
| Jan 31, 2022 | TVTX | ↓ Sell | 1,238 | $27.40 | $34K | Direct | Feb 2, 2022 (2d) |
| Jan 24, 2022 | TVTX | ↓ Sell | 2,063 | $24.98 | $52K | Direct | Jan 26, 2022 (2d) |
| Jan 11, 2022 | TVTX | ↓ Sell | 7,500 | $27.40 | $206K | Direct | Jan 12, 2022 (1d) |
| Aug 17, 2021 | TVTX | ↓ Sell | 1,407 | $17.12 | $24K | Direct | Aug 17, 2021 (0d) |
| May 12, 2021 | TVTX | ↓ Sell | 4,000 | $19.30 | $77K | Direct | May 13, 2021 (1d) |
| Mar 10, 2021 | GNSS | ↓ Sell | 5,456 | $7.42 | $40K | Direct | Mar 12, 2021 (2d) |
| Feb 8, 2021 | TVTX | ↓ Sell | 4,500 | $31.50 | $142K | Direct | Feb 9, 2021 (1d) |
| Feb 3, 2021 | TVTX | ↓ Sell | 3,625 | $28.91 | $105K | Direct | Feb 3, 2021 (0d) |
| Feb 2, 2021 | TVTX | ↓ Sell | 3,625 | $30.75 | $111K | Direct | Feb 2, 2021 (0d) |
| Nov 25, 2020 | RTRX | ↓ Sell | 7,500 | $23.29 | $175K | Direct | Nov 25, 2020 (0d) |
| Nov 16, 2020 | RTRX | ↓ Sell | 7,500 | $23.98 | $180K | Direct | Nov 17, 2020 (1d) |
| Nov 13, 2020 | RTRX | ↓ Sell | 7,500 | $23.61 | $177K | Direct | Nov 13, 2020 (0d) |
| Sep 23, 2020 | RTRX | ↓ Sell | 1,500 | $18.48 | $28K | Direct | Sep 23, 2020 (0d) |
| Sep 22, 2020 | RTRX | ↓ Sell | 1,500 | $18.59 | $28K | Direct | Sep 22, 2020 (0d) |
| May 12, 2020 | RTRX | ↓ Sell | 3,027 | $16.22 | $49K | Direct | May 13, 2020 (1d) |
| Mar 10, 2020 | RTRX | ↓ Sell | 4,000 | $15.02 | $60K | Direct | Mar 12, 2020 (2d) |
| May 16, 2019 | RTRX | ↓ Sell | 2,500 | $18.25 | $46K | Direct | May 16, 2019 (0d) |
| Feb 12, 2019 | RTRX | ↓ Sell | 2,033 | $21.44 | $44K | Direct | Feb 13, 2019 (1d) |
| Dec 21, 2018 | RTRX | ↓ Sell | 7,500 | $21.96 | $165K | Direct | Dec 21, 2018 (0d) |
| Nov 15, 2018 | RTRX | ↓ Sell | 7,500 | $24.02 | $180K | Direct | Nov 16, 2018 (1d) |
| Sep 4, 2013 | LRAD | ↓ Sell | 9,400 | $1.54 | $14K | Direct | Sep 6, 2013 (2d) |
| Dec 11, 2008 | ATCO | ↑ Buy | 2,000 | $0.43 | $870 | By Spouse | Dec 15, 2008 (4d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other TVTX insiders
Open-market trades in the last 12 months
About Laura Clague's insider trades
Laura Clague is Chief Financial Officer at Travere Therapeutics (TVTX). Since Dec 11, 2008, Laura has reported 1 open-market purchase worth $870 and 23 sales worth $2.0M on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (38 filings), option exercises (8 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every TVTX insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.